[Form 4] Kyverna Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Kyverna Therapeutics' chief technology officer reported an option exercise and share sale in Kyverna Therapeutics, Inc. common stock. On 12/15/2025, the officer exercised stock options to acquire 23,998 shares at an exercise price of $4.83 per share and, on the same date, sold 23,998 shares at $12.2 per share. After these transactions, the officer beneficially owned 22,636 shares of common stock directly and held 85,865 stock options.

The filing states that these trades were made under a Rule 10b5-1 trading plan adopted on September 12, 2025, which automates transactions according to preset instructions. The option originally vested 25% of the shares on January 1, 2025, with the remaining portion vesting in equal monthly installments, contingent on continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walker Karen Marie

(Last) (First) (Middle)

C/O KYVERNA THERAPEUTICS, INC.

5980 HORTON ST., STE 550

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		M(1)		23,998	A	$4.83	46,634	D
Common Stock	12/15/2025		S(1)		23,998	D	$12.2	22,636	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$4.83	12/15/2025		M(1)			23,998	(2)	11/05/2033	Common Stock	23,998	$0	85,865	D

Explanation of Responses:

1. The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 12, 2025 in effect at the time of such transactions.

2. 25% of the original number of shares subject to the option vested on January 1, 2025, and 1/48th of the original number of shares subject to the option vests in monthly installments thereafter, subject to the Reporting Person's continuous service.

	/s/ Samantha Eldredge, as Attorney-in-Fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kyverna Therapeutics (KYTX) report in this filing?

The chief technology officer of Kyverna Therapeutics, Inc. (KYTX) reported exercising stock options for 23,998 shares of common stock at $4.83 per share and selling 23,998 shares at $12.2 per share on 12/15/2025.

How many Kyverna Therapeutics (KYTX) shares does the insider own after the reported trades?

Following the reported transactions, the officer directly beneficially owned 22,636 shares of Kyverna common stock and held 85,865 stock options to purchase additional shares.

Were the Kyverna Therapeutics (KYTX) insider trades under a Rule 10b5-1 plan?

Yes. The filing explains that the transactions were made under a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025, which was in effect at the time of the trades.

What position does the reporting person hold at Kyverna Therapeutics (KYTX)?

The reporting person is identified as an officer of Kyverna Therapeutics, Inc., serving as the company’s Chief Technology Officer.

What are the key terms of the Kyverna (KYTX) stock option mentioned in the filing?

The derivative security is a stock option (right to buy) Kyverna common stock at an exercise price of $4.83 per share. The option covers 23,998 underlying shares, became exercisable starting 11/05/2033, and the vesting schedule provides that 25% of the original shares vested on January 1, 2025, with the remainder vesting in equal monthly installments subject to continuous service.

How is the vesting of the Kyverna Therapeutics (KYTX) stock option structured?

The filing states that 25% of the original number of shares under the option vested on January 1, 2025, and 1/48th of the original number of shares vests in monthly installments thereafter, contingent on the reporting person’s continuous service.